CD209 and infection: DC-SIGN and HLA-DR were significantly (P < 0.05, Figure 2) increased compared with uninfected controls for infection with PRVABC59, and addition of ruxolitinib significantly increased both markers compared with infected, non-ruxolitinib treated HC P < 0.05, Figure 2).